Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients

American Journal of Respiratory Medicine

Volumn 2, Issue 1, 2003, Pages 67-74

  Soriano, Joan B ^a,b   Kiri, Victor A ^a   Pride, Neil B ^c   Vestbo, Jørgen ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BAMBUTEROL; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; LONG ACTING DRUG; OXYGEN; SALMETEROL; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEATH; FEMALE; FREQUENCY ANALYSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED KINGDOM;

EID: 0042007981     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256640     Document Type: Article

References (29)

1. The World Health Report 1998. Life in the 21st century: a vision for all. Geneva: World Health Organization, 1998
2. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease: impact of new treatment options. Pharmacoeconomics 2001; 19: 245-54
3. LAIA: Lung & Asthma Information Agency. Trends in emergency hospital admissions for lung disease. St George's Hospital Medical School, London, UK. 1999 Factsheet 99/2
4. The COPD Guidelines Group of the Standards of Care Committee of the BTS. 1998 BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 Suppl. 5: S1-28
5. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303
6. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9
7. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-80
8. O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-42
9. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76
10. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-4
11. Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 2001; 120: 258-70
12. Soriano JB, Vestbo J, Pride NB, et al. Survival of COPD patients after regular use of fluticasone propionate and salmeterol in primary care in the UK. Eur Respir J 2002; 20: 819-25
13. Lawson DH, Sherman V, Hollowell J. The general practice research database: Scientific and Ethical Advisory Group. QJM 1998; 91: 445-52
14. Nazareth I, King M, Haines A, et al. Accuracy of diagnosis on general practice computer system. BMJ 1993; 307: 32-4
15. Hansell A, Hollowell J, Nichols T, et al. Use of the general practice research database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999; 54: 413-9
16. Soriano JB, Maier WC, Egger P, et al. Recent trends of physician-diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789-94
17. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resources in the UK. BMJ 1991; 302: 766-8
18. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-25
19. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000 Jun; 105 (6 Pt 1): 1108-16
20. Calverley PMA, Pauwels RA. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD [abstract]. Am J Respir Crit Care Med 2002; 165 (8): A226
21. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-42
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9
23. Hosmer DW, Lemeshow S, editors. Applied survival analysis: regression modelling of time to event data. New York (NY): John Wiley & Sons, 1999
24. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998
25. Barnes PJ. Inhaled steroids are not beneficial in COPD. Am J Respir Crit Care Med 2000; 161: 342-4
26. Calverley PM. Inhaled steroids are beneficial in COPD. Am J Respir Crit Care Med 2000; 161: 341-2
27. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting B2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-91
28. Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 175-80
29. Strom BL. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons, 2000